Akcea e Ionis reciben una opinión positiva del CHMP de la UE para WAYLIVRATM (volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Massachusetts, y CARLSBAD, California, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ: AKCA), una filial de Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals, Inc....
Akcea e Ionis ottengono dal CHMP parere positivo in UE per WAYLIVRATM (volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Mass. E CARLSBAD, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), una società affiliata di Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals,...
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
March 01, 2019 07:45 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
February 28, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
February 26, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference...
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
February 25, 2019 01:15 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an...
Akcea Therapeutics to Present at Upcoming Investor Conferences
February 20, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast
February 13, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February...
Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting
November 29, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the...
Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии.
November 28, 2018 15:57 ET
|
Akcea Therapeutics, Inc.
Бостон, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Akcea присоединяется к первому Всемирному дню знаний о семейном синдроме хиломикронемии. Сообщество ставит целью повышения знаний в обществе о тяжести...